Prof Mark D Gorrell

@SeanDentBsc @Andrewp37075755 Hi Sean. I agree with you; synergy is more likely than competition.

Hi Andrew, I'm not sure #AVCT's PDC would necessarily compete for Keytrudas market share. Keytruda is an immunotherapy so my assumption could be that pre|CISION chemo would be used in conjunction with this as a complimentary treatment. Trigger immunogenic cell death with Avacta tech which then causes cancer cells within the TME to produce more of the antigen Keytruda targets and that then makes the tumours more visible to the immune system and vulnerable to Keytruda. Caveat, I'm not a biologist and the above opinion is only based on what ive learned from YouTube and the odd book 👍 Sure some of the people smarter than me might be able to answer this hence why I put the hashtag. All the best :)

#AVCT MCap = $525m Projected sales for Enhertu 2030 = $11.2Bn 2030 = $13.9Bn 2031 = $14.3Bn AVA6103 is:- Cheaper to manufacture ✅️ Has vastly reduced side-effects ✅️ Uses a more potent warhead ✅️ Applicable to 90% of solid tumours, unlike Enhertu which is restricted to only tumours that express the antigen HER2 giving a market opportunity many MANY multiples hugher than those figures above. Will AstraZeneca and Daiichi Sankyo just kiss goodbye to those revenues and the tens of billions of sunk costs, or join a bidding war for pre|CISON ? Data is only improving. Tick tock ⏰️ 👀

We all want safer and more effective tumour treatments. This interview presents thoughtful expert clear views on how chemistry and immunology can harmonize for efficacy . youtube.com/watch?v=00Uvub…

FAP is a magnificent target for treating solid tumours, cirrhosis, arthritis, fibrosis in lung, heart or kidney, or endometriosis. FAP targeting increases efficacy while decreasing side effects. My new review is imrpress.com/journal/FBL/30… #centenaryinstitute

@RAH00084 @Blueberrymgmnt Yes, I would love see this idea tested on sera from treated patients. I would also like to see more of the great work done by FAP targeting companies published. My review was written 6 months ago and was limited to discussing published work.

@Blueberrymgmnt @GorrellProf Interesting author speculates that although FAP is not a reliable indicator of cancer, it might vary with increases/decreases in intratumoral FAP+CAF. Thanks for sharing. 34 likes. Whack a GIF on this one.

Excellent from @GorrellProf TLDR; FAP has unusually selective substrate specificity, enabling tumour-restricted activation. “The key power of a prodrug is to greatly increase intratumoural concentration…with precise tumour targeting” #AVCT’s AVA6000 is cited.

@Blueberrymgmnt Avacta is at the forefront of precision oncology and going great, so don’t sweat it.

#AVCT Wonder what they’re seeing in AVA6103 data to be confident enough to recruit TNBC into the AVA6000 P1b? Suggest it’s a combination of data, plus a nudge from somebody that wants a preCISION enabled breast cancer therapeutic.

@RAH00084 To answer your question, consider that 6000 and 6103 have different warheads , so each should be used to treat tumors that are vulnerable to the appropriate warhead.

Do #AVCT think AVA6000 can compete as a monotherapy for TNBC? OR Is the P1b breast arm purely ammunition for AVA6103’s viability?

@thomasrcox @NatureCancer @SyntaraTx @GarvanInstitute @ecmcongress Great science Tom. I enjoyed your talk.

Great fun presenting some of our labs work at the 2024 ECM Pharmacology Congress including our recent @NatureCancer work on pan-LOX inhibitors in pancreatic cancer in collaboration with @SyntaraTx #ECM2024 @GarvanInstitute @ecmcongress | nature.com/articles/s4301… |

We would like to remind you that registration for the next IPS webinar "Many Roads to Inflammation" by Vishva M. Dixit, Vice President of Early Discovery Research at Genentech Inc, on November 20 is still open on IPS website : protease.org. Make sure not to miss this!

@VanessaPirotta @sammyjcomedian @abcmelbourne I agree that fear is a likely cause of this huddle; what caused their fear? Sounds?

We learnt all about our eight armed friends in the sea this morning 🐙 …. I call this the “Fluffnuts effect”. Educating our Melbournian listeners one arm at a time. You decide…. @sammyjcomedian @abcmelbourne #scicomm #radio #whatsupwithanimals segment

Fascinating novel work: HIV infected CD4 cells killed by Val-boro-Pro or 1G244. Congratulations @LShanlab

@jodieingles27 @heartfoundation @GarvanInstitute @dgmacarthur @LauraYeates1 @alexbutters25 @judydo26 @FergusS13 @neeshakrishnan @EbonyR_GC @amy_baker29 Jodie, You exhibit exceptional skill and talent. Your clients and colleagues win.

Not going to lie, when I found out about my fellowship & award, I cried 😭 It’s been a big few years moving my team of 11 to a new institute/university during a pandemic, such a relief when things go well! Huge thanks to @heartfoundation AND MY AMAZING TEAM ❤️⭐️ @GarvanInstitute

@CassHarapas @sethmasters @ReversadeLab @KimSamirah @WEHI_research @ASTARsg @NTUsg Brilliant work. I am thrilled to have helped you.🎉

This work has been a really great collaborative project between the @sethmasters @ReversadeLab and Zhong labs co-led with @KimSamirah and Kenneth Lay. @WEHI_research @ASTARsg @NTUsg

Our work identifying a new autoinflammatory disease in patients with DPP9 deficiency is out! The NLRP1 inflammasome was found to drive disease in mouse and zebrafish models. Mouse models also suggest that dampening IL-1 signalling may be beneficial for patients.

Massively pleased in my role in these discoveries on DPP9 in humans. Now understand DPP9 is fundamental in humans, mice and fish. Congrats to @CassHarapas @sethmasters @ReversadeLab

New research involving humans, mouse models, and zebrafish clarifies how a protein complex called NLRP1 inflammasome encourages immune disorders. @WEHI_research @NTUsg @ASTARsg fcld.ly/65ryg3f

Great to see: DPP9 selective inhibition is much needed.

@kellerlauraj @taylorhnguyen @ajodonoghue @MJNiphakis @MLakeme @mbogyo Excellent work @kellerlauraj - that will urge us to think about what bacterial proteases digest.

So excited to finally be sharing this story!! Thank you to the many collaborators (including @taylorhnguyen in KC Huang's lab, the teams of @ajodonoghue, @MJNiphakis and Ami Bhatt, and my mentor @MLakeme) for helping me and @mbogyo bring this story to life!

Dipeptidyl peptidase 9 triggers BRCA2 degradation and promotes DNA damage repair embopress.org/doi/full/10.15… Excited to share our newest work showing a role for DPP9 in repair of DNA damage. We show that the protease DPP9 determines BRCA2 stability and regulates HR repair!

medrxiv.org/content/10.110… Our snapshot of clinically isolated BA5 virus: 1- Antibodies derived from thousands of donors observes all Omicron variants (esp. BA1, BA2 & BA5) are evasive. 2- Potency of Evusheld and Sotrovimab reduced. 3- Tropism shift back to using TMPRSS2

The pandemic rages, so be careful: In NSW alone there are over 1700 in covid wards.